DCP
REGN icon

Davern Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Davern Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.8M Buy
92,640
+47,840
+107% +$32.6M 9.85% 6
2026
Q1 		$34.6M Sell
44,800
-7,620
-15% -$5.83M 9.5% 2
2025
Q4 		$40.5M Buy
+52,420
New +$35.6M 13.08% 2

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Davern Capital Partners's REGN Position: Q2 2026 in Review

Davern Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 107% in Q2 2026, buying an estimated $32.6M and bringing the position to 92,640 shares worth $57.8M. The position accounts for 9.85% of the portfolio, ranked #6.

Davern Capital Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Davern Capital Partners held 92,640 shares of Regeneron Pharmaceuticals worth $57.8M as of Q2 2026.
  • Davern Capital Partners bought 47,840 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $32.6M.
  • Regeneron Pharmaceuticals made up 9.85% of Davern Capital Partners's portfolio in Q2 2026, its #6 holding.
  • Davern Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.